Nexavar

Nexavar Granted FDA Priority Review for Treatment of Liver Cancer
Posted by Nexavar (Nexavar) on Sat, 25 Aug 2007 23:17:24 +0000

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that the supplemental New Drug Application (sNDA) for Nexavar® (sorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), ...

Nexavar Granted FDA Priority Review For Treatment Of Liver Cancer
“This Priority Review underscores the potential of Nexavar to be a significant advance in the treatment of liver cancer,” said Susan Kelley, MD, vice president, Therapeutic Area Oncology, Bayer HealthCare Pharmaceuticals. ...

Onyx Expects Early 2008 Launch For Nexavar In Liver Cancer
Firm expects more off-label use of Nexavar in liver cancer in second half of 2007.

Bayer And Onyx Submit Supplemental New Drug Application For ...
(Nasdaq: ONXX) today announced that a Supplemental New Drug Application (sNDA) for Nexavar(R) (sorafenib) tablets has been submitted to the US Food and Drug Administration (FDA) for the treatment of patients with hepatocellular ...

Nexavar prolongs survival among Liver cancer patients
The findings of a clinical trial presented by doctors at the American Society of Clinical Oncology meeting in Chicago on Monday provided hope to the deadly liver cancer patients as Nexavar, a drug developed by Onyx Pharmaceuticals Inc. ...